ODT Key Statistics, Chart & Performance
The current stock price of ODT is 1.12 null. In the past month the price decreased by -21.13%. In the past year, price decreased by -94.4%.
ODT Latest News, Press Relases and Analysis
ODT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.57 | 988.98B | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 494.92B | ||
| MRK | MERCK & CO. INC. | 11.47 | 250.76B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.36 | 98.22B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.82B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.43 | 11.17B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.77 | 8.50B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.16B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.26B |
Related stock screener links
About ODT
Company Profile
Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. The company is headquartered in New York City, New York and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company is focused on the development of tesetaxel, a novel chemotherapy agent.
Company Info
Odonate Therapeutics Inc
3 East 28Th Street, 10Th Floor
New York City NEW YORK 10016 US
CEO: Kevin Tang
Employees: 137
Phone: 13322060935.0
Odonate Therapeutics Inc / ODT FAQ
Can you describe the business of Odonate Therapeutics Inc?
Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. The company is headquartered in New York City, New York and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company is focused on the development of tesetaxel, a novel chemotherapy agent.
Can you provide the latest stock price for Odonate Therapeutics Inc?
The current stock price of ODT is 1.12 null. The price decreased by -4.27% in the last trading session.
Does ODT stock pay dividends?
ODT does not pay a dividend.
What is the ChartMill technical and fundamental rating of ODT stock?
ODT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does Odonate Therapeutics Inc have?
Odonate Therapeutics Inc (ODT) currently has 137 employees.
Can you provide the upcoming earnings date for Odonate Therapeutics Inc?
Odonate Therapeutics Inc (ODT) will report earnings on 2022-03-01, before the market open.
ODT Technical Analysis
ODT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ODT. ODT may be in some trouble as it scores bad on both profitability and health.
ODT Financial Highlights
Over the last trailing twelve months ODT reported a non-GAAP Earnings per Share(EPS) of -2.68. The EPS increased by 31.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.5% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ODT Forecast & Estimates
9 analysts have analysed ODT and the average price target is 4.08 null. This implies a price increase of 264.29% is expected in the next year compared to the current price of 1.12.